Spectrum Pharmaceuticals — Investor Presentation (January 2019)
29 slides from Spectrum Pharmaceuticals's investor presentation, Jan 7, 2019
Slide 1: Spectrum Pharmaceuticals Investor Presentation January 2019
A Biopharmaceutical Company Developing Targeted and Novel Therapies in Oncology Spectrum Pharmaceuticals January 2019 | Investor Presentation Joe Turgeon President and CEO Redefining Cancer Care Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements, within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date, regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainti
Slide 3: Focus on Late Stage Pipeline
POZIOTINIB ROLONTIS® (eflapegrastim) Tyrosine Kinase Inhibitor (TKI) targeting exon 20 mutations Results from ZENITH20 cohort 1 in 2H ‘19 Novel long-acting G-CSF for Chemotherapy-induced Neutropenia BLA submitted to FDA December 2018 Focus on Late Stage Pipeline Targeted & Novel Medicines
Slide 4: Focus on Late Stage Pipeline Development Milestone Summary
Tyrosine Kinase Inhibitor (TKI) targeting exon 20 mutations Novel long-acting G-CSF for Chemotherapy-induced Neutropenia Sep ’18 Oral presentation at IASLC World Conference on Lung Cancer Jan ’19 Enrollment completed in cohort 1 (EGFR) of ZENITH20 study H2 ’19 Results of ZENITH20 cohort 1 (EGFR) H2
Slide 5: Poziotinib
Poziotinib Tyrosine Kinase Inhibitor targeting exon 20 mutations Results from ZENITH20 cohort 1 in 2H 2019
Slide 6: Exon 20 Mutations in NSCLC: A Critical Unmet Need
Exon 20 Mutations in NSCLC A Critical Unmet Need No FDA approved targeted therapies NSCLC patients with exon 20 7,700 pts (US) 20,000+ (globally) Patients with non-lung exon 20 solid tumors 8,400 (US)
Slide 7: Poziotinib Demonstrates Improvement Over Standards of Care
Poziotinib Demonstrates Improvement Over Standards of Care Exon 20 (EGFR) Unselected population Exon 20 (EGFR)
Slide 8: Poziotinib Efficacy in EGFR Exon 20 Mutant NSCLC
JV Heymach, University of Texas MD Anderson Cancer Center, USA T790M * * * * * * * * * * * * * * * * * * * Germline T790M +exon20ins * Remains on treatment Poziotinib Efficacy in EGFR Exon 20 Mutant NSCLC 44 Evaluable Patients 43% ORR (confirmed) Heymach, IASLC 19th World Congress on Lung Cancer Ora
Slide 9: Duration of Treatment for EGFR Exon 20
Duration of Treatment for EGFR Exon 20 > 40% of patients remain on therapy (19 of 44 patients) 14% of patients have been on therapy for more than one year (6 of 44 patients) Heymach, IASLC 19th World Congress on Lung Cancer Oral Presentation, September 24, 2018
Slide 10: Poziotinib Efficacy in HER2 Exon 20 Mutant NSCLC
Poziotinib Efficacy in HER2 Exon 20 Mutant NSCLC * * Remains on treatment * * * * 12 Evaluable Patients 42% ORR (confirmed) Heymach, IASLC 19th World Congress on Lung Cancer Oral Presentation, September 24, 2018
Slide 11: Treatment Related AEs in EGFR and HER2
Treatment Related AEs in EGFR and HER2 in >10% of patients (N=63) EGFR related toxicities were manageable and consistent with the class Discontinuation due to poor tolerance was rare and seen in 3% of patients AE All Grade N (%) Grade 3 N(%) Grade 4 N(%) Grade 5 N(%) Diarrhea 44 (69.8%) 11 (17.5%) 0
Slide 12: Poziotinib Efficacy in EGFR Cohort
Poziotinib Efficacy in EGFR Cohort Subset of MD Anderson Investigator-Initiated Phase 2 Study Overall Results N ORR n (%) Confirmed Objective Response Rate (ORR) 30 12 (40.0) Disease Control Rate (DCR), n (%) 30 27 (90.0) Duration on Treatment (months) 30 6.6 Duration on Treatment > 6 months, n (%)
Slide 13: ZENITH20: Spectrum Sponsored Pivotal Phase 2 Study
First-line NSCLC in HER2 exon 20 (n=70) ZENITH20: Spectrum Sponsored Study Pivotal Phase 2 NSCLC Multicenter Study in US, EU, CA Each cohort is an independent study with pre-specified statistical hypotheses and power Primary Endpoint: Objective Response Rate Cohort 1 Enrollment Completed Results Exp
Slide 14: Exon 20 Mutations in Various Tumor Types
Exon 20 Mutations in Various Tumor Types Prevalence of Exon20 NSCLC in Key Markets Region Mutation Exon 20 Frequency (%) Total Number of Exon-20 NSCLC Patients/year US EGFR 2.1% 3.6% 7,700 HER2 1.5% EU EGFR 2.1% 3.6% 8,000 HER2 1.5% Japan EGFR 2.4% 6.4% 5,000 HER2 3.9% TOTAL Patients 20,700 Prevalen
Slide 15: Poziotinib Leading the Way in Treatment of Exon 20 Mutations
Poziotinib Leading the Way in the Treatment of exon 20 Mutations PAN-TUMOR SETTING COMBINATION THERAPY FIRST-LINE THERAPY IN NSCLC MD Anderson Spectrum Actively Pursue Poziotinib’s Full Potential PREVIOUSLY TREATED NSCLC
Slide 16: Poziotinib – 2018 and 2019 Milestones
Poziotinib – 2018 and 2019 Milestones Apr ’18 Publication of initial data of 11 pts with strong ORR (Nature Medicine) Apr ’18 Prevalence data shows promise in multiple solid tumors (AACR) May ’18 Diagnostic partnership with ThermoFisher + stronger licensing agreement with MD Anderson Sep ’18 Oral pr
Slide 17: ROLONTIS (eflapegrastim)
ROLONTIS® (eflapegrastim) Novel, long acting G-CSF for the Management of Chemotherapy-induced Neutropenia BLA submitted to FDA December 2018
Slide 18: ROLONTIS is a Novel Product Targeting a Large Market
ROLONTIS is a Novel Product Targeting a Large Market Targeting a $4 Billion Market BLA Submitted in Dec 2018
Slide 19: Overall ROLONTIS Phase 3 Efficacy
Overall ROLONTIS Phase 3 Efficacy *95% confidence intervals and p-value obtained from bootstrap sampling method ADVANCE (-301) RECOVER (-302) SPI-2012 N=196 Pegfilgrastim N=210 SPI-2012 N=118 Pegfilgrastim N=119 DSN (days) Mean (SD) Median (Range) 0.20 (0.503) 0 (0, 3) 0.35 (0.683) 0 (0, 3) 0.31 (0.
Slide 20: ADVANCE Study Frequency of Severe Neutropenia in Cycle 1
ADVANCE Study Frequency of Severe Neutropenia in Cycle 1 (ITT Population) *95% CI was calculated using Clopper-Pearson method 8.5% Absolute risk reduction of severe neutropenia in cycle 1 -8.5% Difference (CI -16.1, -0.2)
Slide 21: Community Oncology is Critical in CIN
* Data from Dec-16 to Nov-17 Community Oncology is Critical in CIN 21% Non-PHS Hospitals 45% Community Clinic 32% PHS 1% Federal 1% Pharmacy 1% Other LA-G-CSF Unit Volume by Segment
Slide 22: Novel Treatment Offers Strong Position in Competitive Pricing Environment
Novel Treatment Offers Strong Position in Competitive Pricing Environment Drug Costs Pricing Pressures, Price Transparency, Justification of Price Increases Competition in Medicare Marketplace Pressure on Provider Payment, Challenges to Buy & Bill Model Challenging Pricing Constructs, Reference Pric
Slide 23: ROLONTIS Launch Readiness Underway
Supply Chain / Manufacturing Inventory build Filling/packaging Commercialization Develop promotional materials / channel strategy Medical Science Liaison customer engagement Payer engagement Sales force preparation ROLONTIS Launch Readiness Underway
Slide 24: ROLONTIS – 2018 and 2019 Milestones
ROLONTIS – 2018 and 2019 Milestones Feb ’18 ADVANCE study meets primary endpoint Jun ’18 RECOVER study meets primary endpoint Aug ’18 Positive pre-BLA meeting with FDA Q4 ’18 US BLA filing Q1 ’19 FDA acceptance of BLA file 2019 US launch readiness Q4 ’19 Potential FDA decision ✓ ✓ ✓ ✓
Slide 25: Thank you
Thank you Redefining Cancer Care Redefining Cancer Care
Slide 26: Non-GAAP Financial Measures
Non-GAAP Financial Measures In this press release, Spectrum reports certain historical results that have not been prepared in accordance with generally accepted accounting principles (GAAP), including non-GAAP product sales, net and license fees and service revenue, non-GAAP selling, general and adm
Slide 27: Spectrum Pharmaceuticals Non-GAAP Reconciliation
SPECTRUM PHARMACEUTICALS, INC. (a thousands, expect per share amounts) Three Months Ended ‘Nine Months Ended “ree 201 2017 @)_ GAAP product sales, net & license fees and service revenue Ss 25268 os s a S$ 79,930 $ 99,797 = 01) 6.000 325268 § ae S_7929 $94,797 @) GAAP selling, general and administrat
Slide 28: Condensed Consolidated Statements of Operations
aN "ALS, INC. Condensed Consolidated Statements of Operations (thousands, share amovats) ‘Total other (expense) income Loss before income taxes (Provision) benefit for income taxes ‘tose Net loss per share: Diluted Weighted average shares outstanding Basic Died ‘Three Months Ended ‘Nine Months Ended
Slide 29: Spectrum Pharmaceuticals Balance Sheet
SPECTRUM PHARMACEUTICALS, INC. September 30, a s a7 § s December 31, 207
Spectrum Pharmaceuticals — Investor Presentation (January 2019) on 6ix